Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil

被引:23
|
作者
Achatz, Maria Isabel [1 ]
Caleffi, Maira [2 ,3 ]
Guindalini, Rodrigo [4 ,5 ]
Marques, Renato Moretti [6 ,7 ]
Nogueira-Rodrigues, Angelica [8 ,9 ,10 ]
Ashton-Prolla, Patricia [11 ,12 ]
机构
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
[2] Nucleo Mama Porto Alegre, Porto Alegre, RS, Brazil
[3] Assoc Hosp Moinhos de Vento, Porto Alegre, RS, Brazil
[4] Rede DOr Sao Luiz, Oncol DOr, Rio De Janeiro, Brazil
[5] Univ Sao Paulo, Ctr Invest Translac Oncol, Inst Canc Estado Sao Paulo, Hosp Clin,Fac Med, Sao Paulo, Brazil
[6] Hosp Israelita Albert Einstein, Programa Saude Mulher, Sao Paulo, Brazil
[7] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol, Sao Paulo, Brazil
[8] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil
[9] Grp Brasileiro Oncol Ginecol, Belo Horizonte, MG, Brazil
[10] DOM Oncol, Divinopolis, MG, Brazil
[11] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil
[12] Hosp Clin Porto Alegre, Lab Med Genom, Porto Alegre, RS, Brazil
关键词
BRCA MUTATION CARRIERS; NIPPLE-SPARING MASTECTOMY; COST-EFFECTIVENESS; HIGH-RISK; CONTRALATERAL MASTECTOMY; MAINTENANCE THERAPY; WOMEN; PANEL; TP53; SURVIVAL;
D O I
10.1200/JGO.19.00170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEThe objective of this review was to address the barriers limiting access to genetic cancer risk assessment and genetic testing for individuals with suspected hereditary breast and ovarian cancer (HBOC) through a review of the diagnosis and management steps of HBOC.METHODSA selected panel of Brazilian experts in fields related to HBOC was provided with a series of relevant questions to address before the multiday conference. During this conference, each narrative was discussed and edited by the entire group, through numerous drafts and rounds of discussion, until a consensus was achieved.RESULTSThe authors propose specific and realistic recommendations for improving access to early diagnosis, risk management, and cancer care of HBOC specific to Brazil. Moreover, in creating these recommendations, the authors strived to address all the barriers and impediments mentioned in this article.CONCLUSIONThere is a great need to expand hereditary cancer testing and counseling in Brazil, and changing current policies is essential to accomplishing this goal. Increased knowledge and awareness, together with regulatory actions to increase access to this technology, have the potential to improve patient care and prevention and treatment efforts for patients with cancer across the country. (c) 2020 by American Society of Clinical Oncology
引用
收藏
页码:439 / 452
页数:14
相关论文
共 50 条
  • [1] Management of hereditary breast and ovarian cancer
    Hideko Yamauchi
    Junko Takei
    International Journal of Clinical Oncology, 2018, 23 : 45 - 51
  • [2] Management of hereditary breast and ovarian cancer
    Yamauchi, Hideko
    Takei, Junko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 45 - 51
  • [3] Clinical management of hereditary breast ovarian cancer
    Eisinger, F
    PSYCHO-ONCOLOGY, 2000, 9 (05) : 451 - 451
  • [4] Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer
    Rhiem, Kerstin
    Auber, Bernd
    Briest, Susanne
    Dikow, Nicola
    Ditsch, Nina
    Dragicevic, Neda
    Grill, Sabine
    Hahnen, Eric
    Horvath, Judit
    Jaeger, Bernadette
    Kast, Karin
    Kiechle, Marion
    Leinert, Elena
    Morlot, Susanne
    Puesken, Michael
    Schaefer, Dieter
    Schott, Sarah
    Schroeder, Christopher
    Siebers-Renelt, Ulrike
    Solbach, Christine
    Weber-Lassalle, Nana
    Witzel, Isabell
    Zeder-Goess, Christine
    Schmutzler, Rita K.
    BREAST CARE, 2022, 17 (02) : 199 - 207
  • [5] Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations
    Wood, Marie E.
    Garber, Judy E.
    Isaacs, Claudine
    Masood, Shahla
    Bedrosian, Isabelle
    Tung, Nadine
    Chun, Jennifer
    Schnabel, Freya R.
    Arun, Banu K.
    BREAST JOURNAL, 2019, 25 (04): : 575 - 577
  • [6] Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee
    Eisinger, F
    Alby, N
    Bremond, A
    Dauplat, J
    Espie, M
    Janiaud, P
    Kuttenn, F
    Lebrun, JP
    Lefranc, JP
    Pierret, J
    Sobol, H
    Stoppa-Lyonnet, D
    Thouvenin, D
    Tristant, H
    Feingold, J
    ANNALS OF ONCOLOGY, 1998, 9 (09) : 939 - 950
  • [7] DNA diagnosis of hereditary breast and ovarian cancer in Latvia
    Sinicka, O.
    Stengrevics, A.
    Smite, D.
    Eglitis, J.
    Tihomirova, L.
    EJC SUPPLEMENTS, 2004, 2 (03): : 103 - 103
  • [8] Management of familial and hereditary breast and ovarian cancer in Naples
    Pensabene, M
    Tauchmanovà, L
    Colantunoni, OA
    Di Maio, M
    Bianco, AR
    Contegiacomo, A
    ANNALS OF ONCOLOGY, 2000, 11 : 47 - 47
  • [9] Recommendations for medical management of hereditary breast and ovarian cancer:: The INSERM-FNCLCC ad hoc committee
    Eisinger, F
    Alby, N
    Bremond, A
    Dauplat, J
    Espié, M
    Janiaud, P
    Kuttenn, F
    Lebrun, JP
    Lefranc, JP
    Pierret, J
    Sobol, H
    Stoppa-Lyonnet, D
    Thouvenin, D
    Tristant, H
    Feingold, J
    ANNALES D ENDOCRINOLOGIE, 1998, 59 (06) : 470 - 484
  • [10] Recommendations for medical management of hereditary breast and ovarian cancer:: the INSERM-FNCLCC ad hoc committee
    Eisinger, F
    Alby, N
    Bremond, A
    Dauplat, J
    Espié, M
    Janiaud, P
    Kuttenn, F
    Lebrun, JP
    Lefranc, JP
    Pierret, J
    Sobol, H
    Stoppa-Lyonnet, D
    Thouvenin, D
    Tristant, H
    Feingold, J
    ANNALES DE GENETIQUE, 1999, 42 (01): : 51 - 64